Acrivon Therapeutics reported positive interim data for ACR-368 in endometrial cancer and appointed Dr. Mansoor Raza Mirza as CMO. Acrivon Therapeutics, Inc. reported promising data from its ACR-368 ...
Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results